HIV 1 News and Research

RSS

Sweden exceeds UNAIDS HIV goals but faces new challenges

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated cases. However, challenges remain, especially among migrant populations and recent arrivals.

20 Oct 2024

Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus

A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered how a protein linked to the human immune system wards off HIV-1 and herpes simplex virus-1 by assembling structures in the cell that lure in these viruses and then trap them or even take them apart.

9 Oct 2024

Promising new approach to combat HIV

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing antiretroviral therapy.

11 Sep 2024

ProDOL revolutionizes protein quantification in living cells

Scientists have developed a new way of counting labeled proteins in living cells that could become a standard and valuable tool in the field of biomedical research.

8 Aug 2024

Reliability of HIV viral load tests for CAB-LA PrEP questioned in new study

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.

23 Jul 2024

Abacavir linked to increased cardiovascular risk in HIV patients, study finds

CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024

23 Jul 2024

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women.

23 Jul 2024

PrEPVacc HIV vaccine trial shows no reduction in infections

The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.

23 Jul 2024

Elite Controllers: Do their genomes hold the key to curing HIV?

Although South Africa has the largest number of people living with HIV worldwide, strides have been made in controlling the epidemic, especially in the reduction of HIV incidence, testing, and treatment. Equipped with MGI’s advanced sequencing tools and technologies, researchers from the South African Medical Research Council (SAMRC) and University of KwaZulu-Natal (UKZN) are inching closer to finding the answer to the natural control of HIV infection, leading to improved health outcomes and quality of life amongst South Africans.

From MGI 19 Jul 2024

Llama-derived molecules target hidden strains of HIV

A research team at Georgia State University has developed tiny, potent molecules that are capable of targeting hidden strains of HIV. The source? Antibody genes from llama DNA.

17 Jul 2024

Novel antiviral protein SAMD9L blocks HIV-1 and other lentiviruses

Researchers discovered that interferon-stimulated SAMD9L restricts HIV-1 and other lentiviruses by inhibiting viral translation and endosomal trafficking, while SAMD9 enhances HIV-1 replication.

7 Jul 2024

New HIV test targets neglected strains in global cure hunt

A multinational team led by Weill Cornell Medicine investigators developed a test that will help measure the persistence of HIV in people affected by viral strains found predominantly in Africa-;a vital tool in the search for an HIV cure that will benefit patients around the world.

3 Jul 2024

Innovative HIV vaccine approaches yield potential for broad protection against viral strains

A major challenge in developing a vaccine for HIV is that the virus mutates fast-;very fast. Although a person initially becomes infected with one or a few HIV strains, the virus replicates and mutates quickly, resulting in a "swarm" of viral strains existing in a single body.

2 Jul 2024

Lenacapavir: A breakthrough in long-acting HIV prevention for cisgender women

The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.

26 Jun 2024

New US headquarters opened by mass photometry pioneers Refeyn

Refeyn, the company behind pioneering mass photometry technologies, has officially opened its new 10,000 sq. ft. US Headquarters and Customer Interaction Center in Waltham’s Biotech Hub in Greater Boston, Massachusetts.

From Refeyn 10 Jun 2024

New strategy targets rare B cells for effective HIV vaccine development

Germline-targeting epitope scaffold nanoparticles elicit rare broadly neutralizing antibody (bnAb) precursors against human immunodeficiency virus (HIV).

3 Jun 2024

Engineered immunogens show promise in inducing HIV broadly neutralizing antibodies

Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs).

30 May 2024

Breakthroughs in germline-targeting HIV vaccine design for broad protection

Scientists have made several advances in the design of a class of HIV vaccines that could offer broad protection against the virus, according to four new research papers published this week in Science, Science Translational Medicine, and Science Immunology.

17 May 2024

Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

17 May 2024